Paper33467005
Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.
Samuels ER and 1 other. Int J Mol Sci, 2021. Cited by 13 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength. Papers, record 33467005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33467005
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytochrome P-450 CYP3A | Major topic |
| Cytochrome P-450 CYP3A Inhibitors | Major topic |
| Ritonavir | Major topic |
| Binding Sites | |
| Drug Design | |
| Humans | |
| Molecular Docking Simulation | |
| Protein Binding | |
| Quantitative Structure-Activity Relationship |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 GM124169 | NIGMS NIH HHS | United States | P30GM124169 | PubMed and NIH | NIH RePORTER |
| P30 GM133894 | NIGMS NIH HHS | United States | P30GM133894 | PubMed and NIH | NIH RePORTER |
| R01 ES025767 | NIEHS NIH HHS | United States | R01ES025767 | PubMed and NIH | NIH RePORTER |
| ES025767 | NIH HHS | United States | R01ES025767 | PubMed and NIH | NIH RePORTER |
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19649922 | Pharmacokinetic enhancers for HIV drugs. | Curr Opin Investig Drugs | 2009 | https://conductscience.org/library/papers/19649922 | PubMed |
| 2 | 1912325 | Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. | Chem Res Toxicol | 1991 | https://conductscience.org/library/papers/1912325 | PubMed |
| 3 | 26239522 | Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. | J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26239522 | PubMed |
| 4 | 8759309 | Metabolism of organochlorine pesticides: the role of human cytochrome P450 3A4. | Chemosphere | 1996 | https://conductscience.org/library/papers/8759309 | PubMed |
| 5 | 20937904 | Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20937904 | PubMed |
| 6 | 7708670 | ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. | Proc Natl Acad Sci U S A | 1995 | https://conductscience.org/library/papers/7708670 | PubMed |
| 7 | 20124702 | PHENIX: a comprehensive Python-based system for macromolecular structure solution. | Acta Crystallogr D Biol Crystallogr | 2010 | https://conductscience.org/library/papers/20124702 | PubMed |
| 8 | 28590129 | High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4. | Biochemistry | 2017 | https://conductscience.org/library/papers/28590129 | PubMed |
| 9 | 9616191 | Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. | Drug Metab Dispos | 1998 | https://conductscience.org/library/papers/9616191 | PubMed |
| 10 | 25846301 | Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. | Expert Rev Gastroenterol Hepatol | 2015 | https://conductscience.org/library/papers/25846301 | PubMed |
| 11 | 30912932 | Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4. | Biochemistry | 2019 | https://conductscience.org/library/papers/30912932 | PubMed |
| 12 | 32435378 | Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors. | ACS Med Chem Lett | 2020 | https://conductscience.org/library/papers/32435378 | PubMed |
| 13 | 28124606 | Cytochrome P450 Structure, Function and Clinical Significance: A Review. | Curr Drug Targets | 2018 | https://conductscience.org/library/papers/28124606 | PubMed |
| 14 | 27128223 | The ketoconazole legacy. | Clin Pharmacol Drug Dev | 2014 | https://conductscience.org/library/papers/27128223 | PubMed |
| 15 | 32044230 | An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4. | Bioorg Med Chem | 2020 | https://conductscience.org/library/papers/32044230 | PubMed |
| 16 | 10952482 | Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. | Eur J Clin Pharmacol | 2000 | https://conductscience.org/library/papers/10952482 | PubMed |
| 17 | 28118711 | Design, Synthesis, and Structure-Activity Relationship of New Pyrimidinamine Derivatives Containing an Aryloxy Pyridine Moiety. | J Agric Food Chem | 2017 | https://conductscience.org/library/papers/28118711 | PubMed |
| 18 | 30140110 | Direct Synthesis of α-Thio Aromatic Acids from Aromatic Amino Acids. | Tetrahedron Lett | 2018 | https://conductscience.org/library/papers/30140110 | PubMed |
| 19 | 28488354 | Cooperative Light-Activated Iodine and Photoredox Catalysis for the Amination of Csp3 -H Bonds. | Angew Chem Int Ed Engl | 2017 | https://conductscience.org/library/papers/28488354 | PubMed |
| 20 | 9516219 | Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. | N Engl J Med | 1998 | https://conductscience.org/library/papers/9516219 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41608248 | Reformulation of the protein databank for real-time search of geometrical attributes of protein structures. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/41608248 | PubMed |
| 39792691 | Evaluation of Larger Side-Group Functionalities and the Side/End-Group Interplay in Ritonavir-Like Inhibitors of CYP3A4. | Chem Biol Drug Des | 2025 | https://conductscience.org/library/papers/39792691 | PubMed |
| 38992454 | Synthesis and anticancer properties of a hybrid molecule with the testosterone and estradiol head-groups. | Steroids | 2024 | https://conductscience.org/library/papers/38992454 | PubMed |
| 36848848 | Investigating a new C2-symmetric testosterone dimer and its dihydrotestosterone analog: Synthesis, antiproliferative activity on prostate cancer cell lines and interaction with CYP3A4. | Eur J Med Chem | 2023 | https://conductscience.org/library/papers/36848848 | PubMed |
| 36293445 | Crystal Structure of CYP3A4 Complexed with Fluorol Identifies the Substrate Access Channel as a High-Affinity Ligand Binding Site. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36293445 | PubMed |
| 36077379 | Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36077379 | PubMed |
| 36077262 | The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36077262 | PubMed |
| 35934190 | Artemisia extracts differ from artemisinin effects on human hepatic CYP450s 2B6 and 3A4 in vitro. | J Ethnopharmacol | 2022 | https://conductscience.org/library/papers/35934190 | PubMed |
| 35806297 | Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806297 | PubMed |
| 34684008 | Improving Curcumin Bioavailability: Current Strategies and Future Perspectives. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34684008 | PubMed |
| 34110801 | Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4. | J Am Chem Soc | 2021 | https://conductscience.org/library/papers/34110801 | PubMed |
| 34072457 | Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34072457 | PubMed |
| 33933755 | Innovative C2-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4. | Eur J Med Chem | 2021 | https://conductscience.org/library/papers/33933755 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYB5A | 1528 | PubTator's text mining | https://conductscience.org/library/genes/1528 | NCBI Gene |
| CYP2B6 | 1555 | PubTator's text mining | https://conductscience.org/library/genes/1555 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
| CYP4F3 | 4051 | PubTator's text mining | https://conductscience.org/library/genes/4051 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33467005
GET https://conductscience.org/api/papers/v1/33467005/references?page=2